Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real World Clinical Effectiveness of [177Lu]Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients: A Non-Interventional Study

NCT07697989 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07697989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07697989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real World Clinical Effectiveness of [177Lu]Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients: A Non-Interventional Study
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Not yet recruiting
Start date
October 15, 2026
Completion date
January 31, 2027
Enrollment
1,085 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm metastasis, prostatic neoplasms, castration-resistant